Advantages and Limitations of Bacteriophages for the Treatment of Bacterial Infections

Bacteriophages (BPs) are viruses that can infect and kill bacteria without any negative effect on human or animal cells. For this reason, it is supposed that they can be used, alone or in combination with antibiotics, to treat bacterial infections. In this narrative review, the advantages and limita...

Full description

Saved in:
Bibliographic Details
Main Authors: Nicola Principi (Author), Ettore Silvestri (Author), Susanna Esposito (Author)
Format: Book
Published: Frontiers Media S.A., 2019-05-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_33da45ea05f54f45b4cb7e7fb5f08a5a
042 |a dc 
100 1 0 |a Nicola Principi  |e author 
700 1 0 |a Ettore Silvestri  |e author 
700 1 0 |a Susanna Esposito  |e author 
245 0 0 |a Advantages and Limitations of Bacteriophages for the Treatment of Bacterial Infections 
260 |b Frontiers Media S.A.,   |c 2019-05-01T00:00:00Z. 
500 |a 1663-9812 
500 |a 10.3389/fphar.2019.00513 
520 |a Bacteriophages (BPs) are viruses that can infect and kill bacteria without any negative effect on human or animal cells. For this reason, it is supposed that they can be used, alone or in combination with antibiotics, to treat bacterial infections. In this narrative review, the advantages and limitations of BPs for use in humans will be discussed. PubMed was used to search for all of the studies published from January 2008 to December 2018 using the key words: "BPs" or "phages" and "bacterial infection" or "antibiotic" or "infectious diseases." More than 100 articles were found, but only those published in English or providing evidence-based data were included in the evaluation. Literature review showed that the rapid rise of multi-drug-resistant bacteria worldwide coupled with a decline in the development and production of novel antibacterial agents have led scientists to consider BPs for treatment of bacterial infection. Use of BPs to overcome the problem of increasing bacterial resistance to antibiotics is attractive, and some research data seem to indicate that it might be a rational measure. However, present knowledge seems insufficient to allow the use of BPs for this purpose. To date, the problem of how to prepare the formulations for clinical use and how to avoid or limit the risk of emergence of bacterial resistance through the transmission of genetic material are not completely solved problems. Further studies specifically devoted to solve these problems are needed before BPs can be used in humans. 
546 |a EN 
690 |a antibiotics 
690 |a antimicrobial resistance 
690 |a bacterial infection 
690 |a bacteriophages 
690 |a multi-drug resistance 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Frontiers in Pharmacology, Vol 10 (2019) 
787 0 |n https://www.frontiersin.org/article/10.3389/fphar.2019.00513/full 
787 0 |n https://doaj.org/toc/1663-9812 
856 4 1 |u https://doaj.org/article/33da45ea05f54f45b4cb7e7fb5f08a5a  |z Connect to this object online.